A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Clinical trial NCT06750094 · RECRUITING
Trial details
- NCT number
- NCT06750094
- Sponsor
- Janssen Research & Development, LLC
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-12-12
- Primary completion
- 2027-12-15
- Enrollment
- 700
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.